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Objectives: In chronic kidney disease–mineral and bone disorder (CKD-MBD),most treatment decisions are
guided by parathyroid hormone (PTH) levels. Here, we aimed at assessing the technical and clinical performance
of two novel automated biointact PTH(1–84) assays, from Roche Diagnostics (Ro) and DiaSorin (DS), in hemo-
dialysis patients.
Design and methods: We recorded demographics, dialysis treatment characteristics, pharmacotherapy for
CKD-MBD and laboratory work-up. Statistical methods included Passing–Bablok, and multiple linear regression.
Results: 121 patients, dialyzing on average for 3.5 years (range: 0.1–22.5), with serum phosphate 1.9±
0.6 mmol/L (mean±SD), participated in the study. Median serum concentration for intact PTH was 223 ng/L
(range: 5–2844), and for biointact PTH(1–84) was 136 ng/L (Ro; range: 1–1644), respectively 138 ng/L (DS;
range: 4-1580). Both biointact assays were signiﬁcantly correlated (r=0.98; Ro=0.87×DS+19.60). Bland–
Altmann plots revealed an average bias ±2 SD of 10±27 ng/L below 200 ng/L, and −32±157 ng/L above
200 ng/L (Ro minus DS). The variably adjusted association between PTH and serum phosphate was very similar,
regardless of the PTH assay, but this was not the case for PTH-derivedmeasures (ratios biointact/intact; differences
intact minus biointact). (Log)PTH concentrations as well as serum phosphate were signiﬁcantly associated with
serum creatinine, but only in patients with >0 mL urine per day.
Conclusions: Results from Roche and DiaSorin biointact PTH(1–84) assays were well correlated, but showed
increased deviations at higher concentrations. Biointact PTH(1–84) levels are roughly two third of intact PTH.
The association between PTH and serum creatinine may depend on residual renal clearance of PTH and/or
serum phosphate.© 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.Introduction
Parathyroid hormone is an 84-amino acid polypeptide [PTH(1–84)],
produced by the parathyroid glands and released in response to
decreased extracellular ionized calcium (Ca2+) [1]. PTH has a short half
life (2–4 min) and raises serum Ca2+ by stimulating its release from
bone, its reabsorption in the kidney, and by increasing calcitriol
[1,25(OH)2D3] synthesis [1]. Chronic kidney disease (CKD) patients may
develop secondary hyperparathyroidism with rising PTH levels, when
the glomerular ﬁltration rate (GFR) falls below 60 mL/min/1.73 m2
(=CKD stage 3) [2], mechanistically triggered by the accumulation of
phosphate, and involving a feedback loop between PTH and ﬁbroblast
growth factor (FGF)-23 [3–7]. In consequence, renal osteodystrophy, a
bone remodeling disorder affects nearly all CKD patients who reach
renal replacement therapy (GFR b15 mL/min/1.73 m2=CKD stage 5).na, Department of Nephrology
stria.
(M. Hecking).
mists. Published by Elsevier Inc. OpExtensive efforts have been made to implement imaging technolo-
gies [8–10] and serum markers [11,12] as routine diagnostic tools for
renal osteodystrophy, while histological analysis is the gold standard
[13,14]. However, to differentiate between increased and decreased
bone turnover [13,15] and its respective treatment, which includes
phosphate binders, vitamin D, calcimimetics, and parathyroidectomy,
most physicians rely on PTH measurements. Recent guidelines on
chronic kidney disease-mineral and bone disorder (CKD-MBD) recom-
mend that PTH levels should bemaintainedwithin the range of approx-
imately 2 to 9 times the upper limit of normal of the PTH assay [16,17].
Because PTH levels are thus guiding treatment decisions in
CKD-MBD, the quality of the PTH assay is of paramount importance
[1]. First-generation competitive PTH assays used only one antibody,
and detected a large proportion of PTH fragments, which are mainly
produced in the liver, eliminated by the kidney, and exhibit a longer
half-life than PTH(1-84), such that they may accumulate in CKD
patients [1,18–20]. Second-generation immunometric PTH assays,
falsely entitled ‘intact PTH assays’, were thought to measure only
full-length PTH(1-84), but also detect N-truncated fragments, and
mostly PTH(7–84) [21], which may act antagonistically to PTH(1–84)
via its distinct receptor [15,22–24].en access under CC BY-NC-ND license.
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Previous recommendations stating that PTH levels should be maintained
within a range of 150–300 ng/L [2] were based on the Nichols Institute
Diagnostics' Allegro® intact PTH immunoradiometric assay [1]. This
assay however, is no longer available, because Nichols Institute left the
market [26], after T. Cantor showed considerable variation between
their manual Allegro® test, and the following automated Nichols
Advantage™ intact PTH assay [25,27]. Theﬁrst third generation ‘biointact’
PTH(1–84) assay was described in 2001 [28]. Manual biointact PTH
assays are currently available from Scantibodies and Immutopics, and
have previously been compared with the automated biointact PTH
(1–84) assay from Nichols [29,30], which is also no longer available.
In the present study on hemodialysis patients, we aimed at
assessing the technical and clinical performance of two novel fully
automated biointact PTH(1–84) assays, the Elecsys® PTH(1–84)
assay from Roche Diagnostics and the LIAISON® PTH(1-84) assay
from DiaSorin.Patients and methods
We obtained approval from the Ethics Committee of the Medical
University of Vienna (EK-no. 452/2010) to carry out this open, non-
interventional, observational cohort study. All patients who were un-
dergoing uninterrupted hemodialysis or hemodiaﬁltration at the
Chronic Hemodialysis Unit of the Division of Nephrology and Dialysis,
Medical University of Vienna, were invited to participate, and were
asked to provide written, informed consent. The study adhered to the
Declaration of Helsinki.Data extraction and laboratory parameters at baseline
Patient baseline characteristics included age, sex, height, time on di-
alysis, and residual renal function, which was deﬁned as >0 mL urine
per 24 h, and evaluated during the study period. We also recorded the
dialysate calcium concentration, treatment with phosphate binders,
vitamin D and cinacalcet against CKD-MBD. A routine control of labora-
tory parameterswasperformed after the long interdialytic interval in all
patients of our center; those agreeing to participate in the study were
included prior to this quarterly control.
Blood was drawn from the patient's hemodialysis access, after
discarding at least 10 mL in patients with venous catheters to avoid
contamination with catheter lock solutions. Blood was always
obtained prior to the hemodialysis session to rule out contamination
with heparin used for the dialysis treatment, and was allowed to
clot at room temperature before it was mechanically transported or
personally delivered to the central laboratory (estimated time
30–120 min). Laboratory processing (administration, centrifugation
to obtain serum aliquoting) took about another 30 min, such that
nourishment of samples was completed within 60–180 min, and
PTH stability could reasonably be ensured [31,32]. Routine laboratory
work-up included total calcium, hemoglobin, albumin, ferritin, phos-
phate, creatinine (all measured from fresh sera by clinical chemistry
analyzer AU5400, Beckmann Coulter, USA), as well as intact PTH
and vitamin D metabolites. The latter were analyzed by immunoas-
says in several sample aliquots, which were temporarily stored frozen
at −80 °C.
After thawing samples, both intact PTH and biointact PTH(1–84)
levels were measured with Roche reagents by a Cobas® e411R immu-
noassay analyzer (Roche Diagnostics, Germany). For comparison pur-
poses, biointact PTH(1–84) kits from DiaSorin were run on a
LIAISON® analyzer (DiaSorin, USA). Vitamin D metabolites 25(OH)D3
and 1,25(OH)2D3 were measured with kits purchased from DiaSorin
by the Liason®analyzer, and by radioimmunoassay after sample extrac-
tion, respectively.Statistics
Descriptive statistics, speciﬁcally mean±standard deviation (SD),
median (minimum; maximum), and relative frequency were used to
portray patient baseline characteristics, treatment data and laborato-
ry values. Method comparisons between the three PTH assays were
achieved by Passing–Bablok regression ﬁts [33]. The agreement
between both biointact assays was analyzed by Bland–Altman plots
[34].
For clinical evaluations the values for PTH and PTH fragment
concentration were log-transformed, because of their skewed distribu-
tion (excluding calculations of PTH-ratios). Univariate linear regression
served to determine the association between clinically reasonable pre-
dictors for intact PTH, as well as their signiﬁcance level. Multiple linear
regression was used to analyze the association between several PTH
variables as outcomeand serumphosphate as the clinicallymost impor-
tant predictor, with several levels of adjustment. Adjustments were
chosen from statistically signiﬁcant predictors for intact PTH by univar-
iate linear regression as described above. The samemodelswere used to
calculate the associations between either PTH-fragment concentrations
(deﬁned by intact PTH minus Roche and DiaSorin biointact PTH(1–84)
results, respectively) or PTH-ratios (deﬁned by Roche or DiaSorin
biointact PTH(1–84) results divided by intact PTH) and serum phos-
phate. The latter analyses were based on the aforementioned reports
that PTH(1–84), but not N-truncated PTH fragments represented the
active form of PTH [15,21–24]; ratios represent the proportion of active
per total (active+inactive=intact) PTH. With patients grouped
according to residual renal function, again univariate linear regression
ﬁt was employed to analyze the association between PTH levels mea-
sured by the various assays and serum creatinine.
For calculations we used MS Excel 2003, Evapak_3.1 software for
Passing Bablok regression ﬁt (provided by Roche Diagnostics), SAS
9.2 for Windows (The SAS Institute, Inc., Cary, NC) and Stata 9.0
(Stata Corp, College Station, TX).
Results
Of all 130 patients who were invited, 121 patients agreed to
participate in the present study and provided written, informed
consent. Patient demographics, dialysis treatment characteristics,
pharmacotherapy for CKD-MBD, and laboratory parameters with re-
spective reference ranges are provided in Table 1. Roche or DiaSorin
biointact PTH(1–84) levels were about two third of intact PTH con-
centrations on average; PTH fragment concentrations account for
the last third. As previously reported for an independent, large inter-
national dataset [35], serum phosphate levels in our study were high
(1.9±0.6 mmol/L) despite treatment with phosphate binders in 96%
of the cohort. Total calcium levels were at the lower range of normal
(2.2±0.2 mmol/L). Average albumin levels were still within the ref-
erence range. As expected, creatinine was elevated, while vitamin D
metabolites were suppressed. Ferritin and hemoglobin levels were
within the target ranges for hemodialysis patients. Whereas 54% of
dialysis patients internationally have been shown to be treated with
some form of vitamin D [36], and 20% are treated with cinacalcet
[37], vitamin D and cinacalcet treatments were applied to 46% and
24% of patients in the present study, respectively.
Method comparison of the PTH assays
Amethod comparison of both biointact PTH(1–84) assays yielded the
Passing–Bablok regression line Ro=0.87×DS+19.6 (95% conﬁdence in-
terval [CI] of slope: 0.84–0.92; 95% CI of intercept: 15.0–23.4; r²=0.97,
pb0.0001). A Bland–Altmann plot revealed that the average bias ±2
SD between the assays (Ro minus DS) was 10±27 ng/L up to 200 ng/L.
Above 200 ng/L, the bias was −32±157 ng/L (Fig. 1). Both biointact
PTH(1–84) assays correlated well with intact PTH, but their results
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Fig. 1. Agreement between assays for biointact PTH(1–84). Bland–Altmann plot [34].
Up to 200 ng/L the average bias ±2 SD between the methods (Roche minus DiaSorin)
was 10±27 ng/L; above 200 ng/L the bias was −32±157 ng/L.
Table 1
Demographics, laboratory values and treatment characteristics.
All Normal range
Number of patients 121
Age [years] 59±19
Female 42%
Height [m] 1.68±0.10
Weight [kg] 70±17
Time on dialysis [years] 3.5 (0.1–22.5)
Residual renal function unknown 4%
Residual renal function >0 mL urine/day 72%
Intact PTH [ng/L] 223 (5–2844) 15–65
DiaSorin biointact PTH(1–84) [ng/L] 138 (4–1580) 6.5–36.8
Roche biointact PTH(1–84) [ng/L] 136 (1–1644) 14.9–56.9
Intact PTH minus DiaSorin biointact
PTH(1–84) [ng/L]
89 (0–1264)
Intact PTH minus Roche biointact PTH
(1–84) [ng/L]
82 (4–1199)
DiaSorin Biointact PTH(1–84)/intact PTH 0.61±0.14
Roche Biointact PTH(1–84)/intact PTH 0.64±0.09
Total serum calcium [mmol/L] 2.2±0.2 2.2–2.65
Serum phosphate [mmol/L] 1.9±0.6 0.81–1.45
Hemoglobin [mmol/L] 6.8±0.9 (males)
6.6±0.8 (females)
8.4–11.2 (males)
7.5–9.9 (females)
Serum creatinine [μmol/L] 760±256 b100
Serum albumin [g/L] 38±4 34–48
Serum ferritin [pmol/L] 649±575 (males)
658±431
(females)
45–674 (males)
22–270
(females)
25-Hydroxyvitamin D [nmol/L] 22±17 50–125
1,25-Dihydroxyvitamin D [nmol/L] 39±23 65–172
Dialysate calcium concentration
1.25 mmol/L 26%
1.50 mmol/L 69%
1.75 mmol/L 5%
Phosphate binder treatment 96%
Aluminum hydroxide 77%
Sevelamer hydrochloride or sevelamer
carbonate
45%
Lanthanum carbonate 15%
Calcium acetate/magnesium
carbonate
7%
Calcium carbonate 37%
Vitamin D treatment 46%
Alfacalcidol i.v. 19%
Paricalcitol i.v. 11%
Calcitriol p.o. 16%
Cinacalcet treatment 24%
Categorical variables are reported as counts and frequencies. Continuous variables are
reported as medians and ranges (in parentheses), or means±standard deviations.
1647M. Hecking et al. / Clinical Biochemistry 45 (2012) 1645–1651were about one third lower. The 95%CI of slopes marginally overlapped,
but there was no overlap of 95% CI of intercepts (Fig. 2).0
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Fig. 2. Association between biointact PTH(1–84) and intact PTH. Passing–Bablok re-
gression [33]. Regression line 1: DS PTH(1–84)=0.66×intact PTH−9.11 (95% CI of
slope: 0.63 to 0.70; 95% CI of intercept−15.70 to−4.29; r2=0.947, pb0.001). Regres-
sion line 2: Ro PTH(1–84)=0.60×intact PTH+9.00 (95% CI of slope: 0.58 to 0.62; 95%
CI of intercept 4.76 to 12.71; r2=0.988, pb0.001).Practical relevance of the differences in PTH assays
Whether differences among the PTH assays might be practically
relevant, was tested in a two-step approach: in the ﬁrst step, based on
clinical considerations, we chose various factors of which we hypothe-
sized that they would be associated with (log-transformed) intact PTH
concentrations and veriﬁed the statistical signiﬁcance of this association
(Table 2). As expected from the relations already shown in Fig. 2, (log)
biointact PTH(1–84) concentrations were the strongest predictors for
(log) intact PTH. Additionally, serum phosphate, age, treatment with
paricalcitol, treatment with cinacalcet, and – interestingly – serum
creatinine concentrations signiﬁcantly predicted intact PTH levels.
In the second step, we designed a multivariate regression analysis
with log PTH and PTH-derived values as outcome variables and serum
phosphate as the predictor. Based on clinical considerations, we chose
5 levels of adjustment, whose association with PTH had been con-
ﬁrmed to be signiﬁcant in the present dataset (Table 2). We observed
that regardless of the PTH assay, the strength of the associationbetween log-transformed PTH and serum phosphate was very similar
in an unadjusted regression model as shown by only negligible
differences in p-values or estimated coefﬁcients of determination
(Table 3).
When we added the chosen covariables for adjustment one by one
(i.e. age, residual renal function, total serum calcium, treatment with
vitaminD or cinacalcet), in order to systematically assess for confounding
in our multiple regression analysis, the signiﬁcance of the association
between serum phosphate and log PTH was lost, for the remaining
models, indicating that the association between serum phosphate and
PTH was not independent of the performed adjustments. Surprisingly
however, even in most of the adjusted models, the concentration of
log-transformed N-truncated PTH fragments (PTH(7–84) and others)
correlated signiﬁcantly with serum phosphate. The ratio of Roche
biointact PTH(1–84)/intact PTHcorrelated signiﬁcantlywith serumphos-
phate irrespective of adjustment. All correlations were lost with ratios
calculated from results of DiaSorin assays.
Role of residual renal function
When we stratiﬁed the principal laboratory parameters of this
dataset based on the presence or absence of residual renal function,
we noted higher serum creatinine, and higher PTH levels, despite
lower serum phosphate concentrations in patients without residual
renal function (Suppl. Table 1). Patients with residual renal function
were also on hemodialysis for a shorter amount of time. Regardless
of the PTH assay, log-transformed PTH levels were signiﬁcantly asso-
ciated with serum creatinine, but exclusively in patients with residual
renal function (Fig. 3). Despite higher serumphosphate in patientswith
residual renal function, phosphate levels were – as PTH – positively as-
sociated with higher creatinine concentrations. Again, this association
Table 2
Univariate predictors for log intact PTH.
r2 p
Log DiaSorin biointact PTH(1–84) 0.961 b0.001
Log Roche biointact PTH(1–84) 0.978 b0.001
Age 0.119 b0.001
Serum phosphate 0.052 0.012
Total serum calcium 0.059 0.008
Serum creatinine 0.056 0.009
Vitamin D treatment (reference: untreated) 0.035 0.041
Etalpha i.v. (reference: untreated) 0.015 0.180
Paricalcitol i.v. (reference: untreated) 0.041 0.027
Calcitriol p.o. (reference: untreated) 0.002 0.601
Cinacalcet treatment (reference: untreated) 0.090 b0.001
r2=coefﬁcient of determination. Boldface indicates statistical signiﬁcance (pb0.05).
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(creatinine=176.8×phosphate−380.12; r²=0.198 pb0.001). In pa-
tients without residual renal function however, the coefﬁcient of deter-
mination was r2=0.071 (p=0.134).Discussion
Because the production of the automated biointact PTH(1–84) assay
from Nichols Institute Diagnostics was stopped in 2005, there is someTable 3
Association of PTH-related outcome variables with serum phosphate as predictor, with var
Model 1 Model 2 Model 3
Outcome variable:
log intact PTH
r2 0.052 0.141 0.147
p 0.012 0.098 0.186
Outcome variable:
log DiaSorin biointact
PTH(1–84)
r2 0.042 0.122 0.134
p 0.024 0.148 0.257
Outcome variable:
Log Roche biointact
PTH(1–84)
r2 0.037 0.125 0.138
p 0.034 0.205 0.361
Outcome variable:
log (intact PTH minus
DiaSorin biointact
PTH(1–84))
r2 0.096 0.161 0.170
p b0.001 0.008 0.008
Outcome variable:
log (intact PTH minus
Roche Biointact
PTH(1–84))
r2 0.073 0.162 0.162
p 0.003 0.031 0.085
Outcome variable:
DiaSorin biointact
PTH(1–84)/intact PTH
r2 0.002 0.002 0.017
p 0.631 0.659 0.594
Outcome variable:
Roche biointact
PTH(1–84)/intact PTH
r2 0.066 0.072 0.110
p 0.005 0.012 0.008
Multiple regression analysis. PTH, as measured by intact PTH and biointact PTH(1–84) as
coefﬁcients of determination (r2) and the p-values represent the association between the ou
statistical signiﬁcance (pb0.05). Levels of adjustment: model 1=unadjusted. Model 2=mod
(24 h urine >0 mL/day). Model 4=model 3+adjustments for total serum calcium. Model 5
Cinacalcet treatment.interest in high-performing assays. In the present study on hemodialysis
patients, we compared total PTH, so called “intact PTH” concentrations,
with “biointact” PTH(1–84) levels, obtained with assays from two
suppliers (DiaSorin and Roche). All of these assays were handled on
fully automated platforms. Besides conventional method comparisons,
we also tested these PTH assays in the clinical setting, by performing
linear regression analyses with various levels of adjustment.
The principal study ﬁnding was that the PTH results obtained with
the various assays correlated well among one another. On average,
levels obtained with assays for biointact PTH(1–84) reached only
about two third of intact PTH concentrations. In a previous study [38],
the ratio of biointact PTH(1–84) from Nichols Institute to intact PTH,
measured with Nichols' Allegro® assay was 0.51±0.34 in hemodialysis
patients, but in our studywas 0.61±0.14 and 0.64±0.09 (Table 1). The
results from both studies indicate that PTH levels can only be approxi-
mated from intact PTH assays to biointact PTH(1–84) assays, and vice
versa.
Despite the tight correlation between biointact PTH(1-84) results
obtained with Roche and DiaSorin assays, some differences were ob-
served. Speciﬁcally, a Bland–Altmann plot revealed that the Roche
assay yields systematically higher values than the DiaSorin assay at
concentrations of biointact PTH(1–84) below 200 ng/L. Vice versa,
the Roche assay yields systematically lower values than the DiaSorin
assay at concentrations of biointact PTH(1–84) above 200 ng/L.
Thus, the assays may not be used interchangeably; slight differences
in calibration, matrix effects or avidity of antibodies may explain theious levels of adjustment.
Model 4 Model 5 Model 6
0.175 0.208 0.267
0.237 0.140 0.106
0.174 0.210 0.246
0.334 0.202 0.172
0.189 0.208 0.249
0.468 0.346 0.299
0.171 0.230 0.317
0.008 0.002 b0.001
0.170 0.223 0.308
0.101 0.042 0.024
0.053 0.066 0.181
0.484 0.599 0.905
0.248 0.349 0.106
0.001 b0.001 0.157
says was transformed to various outcome variables (logarithm, difference, ratio). The
tcome and the independent variable phosphate (not for the model), boldface indicating
el 1+adjustments for age. Model 3=model 2+adjustments for residual renal function
=model 4+adjustments for vitamin D treatment. Model 6=model 5+adjustments for
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Fig. 3. Association between serum creatinine and PTH depends on renal function. PTH concentrations were log-transformed. A: patients with >0 mL urine/day (n=83), B: patients
without residual renal function (n=33).
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from the fast “kinetic” test formats. The short incubation times until
signal measurement differ between the automation platforms and are
most likely insufﬁcient to reach the chemical equilibrium. In any case,
according to the manufacturers (E. Fidler [DiaSorin], personal commu-
nication, 31-may-2012 andA. Kyriatsoulis [RocheDiagnostics], personal
communication, 8-december-2010), the biointact PTH(1–84) assays
(from Roche and DiaSorin) were related to the biointact PTH(1–84)
assay (“CAP”) from Scantibodies Inc. (USA); the Roche assay was also
standardized against the international WHO standard 95/646, indicat-
ing that the results are likely more reliable.
The positive association between serum creatinine and PTH in
hemodialysis patients is intriguing at ﬁrst sight, but has previously
been reported [38]. It is a routine practice at the Chronic Hemodialysis
Unit of the Medical University of Vienna to measure 24 hour urine in
all patients. Based on this information, we were able to show that a
signiﬁcant correlation between PTH and serum creatinine exists only
in patients with residual renal function. Since this correlation was not
just weaker, but in fact absent in patients with 0 mL urine/day,
nutritional status leading to higher muscle and thereby higher serum
creatinine can be ruled out as the suggested causal factor [38]. Speciﬁ-
cally, if nutritional status had an inﬂuence, the correlation would have
to bemuch stronger, and certainly not absent in patientswithout residual
renal function, where the level of serum creatinine does not depend on
residual renal clearance, but only on dialysis quality and muscle mass.
Phosphate levels are known to be higher in patients with higher
PTH. Counter-intuitively, average serum phosphate was lower in the
subgroup of patients without residual renal function, as compared
to patients with residual renal function in the present study (Suppl.
Table 1). This result does not rule out that higher serum phosphate
is associated with higher serum creatinine only among patients
with residual renal function, as we observed in the present dataset.In consequence, the latter relationship could have driven the associa-
tion between creatinine and PTH. As another alternative, biointact
and fragmented PTH may – albeit to a small degree – be cleared by
the kidneys, even in patients that are already on hemodialysis. Future
research should determine the mechanism behind the association
shown in this study, and also the possible consequences. For example
it might be interesting to examine if PTH, which is known to be asso-
ciated with mortality in dialysis patients [39,40], is a stronger deter-
minant for outcomes in patients with residual renal function than in
patients without residual renal function.
In clinical settings, we tested whether the different PTH assays may
lead to disparate conclusions. Our regression model with serum
phosphate as predictor and PTH as the outcome was designed on the
pathophysiological basis that, more than anything, the accumulation
of serum phosphate causes the PTH to rise in CKD patients [3]. In this
model, we noted a stronger association between serum phosphate
and N-truncated PTH fragments than between serum phosphate and
biointact PTH(1–84), especially after adjusting for cinacalcet use,
which is – by clinical indication – a strong predictor of high PTH levels.
The reasons for this ﬁnding remain speculative. PTH(7–84) fragment
has been found to have a weak anticalcemic effect [22,24]. Moreover,
the CHOICE study previously showed that biointact PTH(1-84) levels
are slightly better predictors for mortality than intact PTH levels [41].
However, the latter two results are unlikely explanations for a stronger
association between PTH fragments and serumphosphate, than between
biointact PTH(1-84) and serum phosphate. By contrast, a stronger
dependency of both, serum phosphate concentrations as well as PTH
fragments on renal clearancemight offer a better explanation. In compar-
ison to PTH fragments, newly synthesized full-length PTH measured by
the biointact PTH(1–84) assays might thus be more reﬂective of acute
PTH changes secondary to changes in serum calcium, but less reﬂective
of the serum phosphate accumulation over time.
1650 M. Hecking et al. / Clinical Biochemistry 45 (2012) 1645–1651When the ratio of biointact PTH(1–84)/intact PTH was used as the
outcome, the results in the multivariate analysis shown in Table 3
were strikingly different for either one of the biointact assays. This
ratio reﬂects the idea that – if PTH(1–84) represented the active form
of PTH while results obtained with the intact PTH assay were ‘falsiﬁed’
by inactive fragments – then, the more accurate the assay would be, the
more signiﬁcant the relationship in the model. We found that only the
Roche biointact assay yielded ratios of biointact PTH(1–84)/intact PTH
which showed signiﬁcant associations with serum phosphate. Apart
from accuracy, in any case, these results may indicate that both biointact
PTH(1–84) assays might measure slightly different PTH(1–84).
Our study has several limitations.Wewere unable to discriminate be-
tween high and low turnover renal osteodystrophy, because we did not
perform bone biopsies, and are also lacking imaging data. Moreover,
our hypothesis that the association between PTH and serum creatinine
depends on renal clearance of PTH could have been strengthened by
determining the association between PTH and glomerular ﬁltration rate,
but we are lacking this data, which cannot be retrieved retrospectively.
Our study is also not the ﬁrst to have evaluated the comparability of as-
says for biointact PTH(1–84) and intact PTH(1–84). However, our analy-
ses add important information to previous studies [29,30,42], not only
because we evaluated two previously unpublished automated assays
for biointact PTH(1–84), and clariﬁed analytical features that another
study has found for two unrelated assays [30], but also because we
were able to provide essential clinical information in awell characterized
cohort (Tables 1–3, Suppl. table 1).
In conclusion, the results from novel automated assays for biointact
PTH(1–84) from Roche Diagnostics and DiaSorin correlate very well,
but should not be used interchangeably. The same applies – to a greater
extent – to using assays for intact PTH, where concentrations are more
than 50% higher than biointact PTH(1–84) levels. All analyzed PTH
assays can help guide treatment decisions, if the speciﬁc range of the
assay is taken into account, and given that mostly the changes in PTH
levels are important for decisions. Serum creatinine associated positively
with PTH in patients with residual renal function, regardless of the PTH
assay. This relationshipmay have been driven by residual renal clearance
of PTH and could in future become useful as a prognostic marker.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.clinbiochem.2012.08.006.
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